The FDA has approved AstraZeneca/Alexion’s gefurulimab (Klygefa) for the treatment of adults with AChR antibody-positive generalized myasthenia gravis, supporting once-weekly subcutaneous self-injection via an automatic injector.
Source:AJMC · Read the original article
Leave a Reply